Dupilumab (Dupixent) was found to effectively treat atopic dermatitis (AD) among various racial subgroups, according to the findings of a recent study.
In the post hoc analysis, researchers pooled data from three phase 3 trials (LIBERTY AD SOLO 1, SOLO 2, and CHRONOS) that accessed the efficacy of dupilumab compared with placebo among racial subgroups (n=2058). The main outcomes included the mean and percent change from baseline to week 16 on the Eczema Area and Severity Index (EASI), Peak Pruritis Numerical Rating Scale (NRS), Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM), as well as Investigator Global Assessment (IGA) and pain or discomfort, measured using the European Quality of Life-5 Dimensions 3 level questionnaire.
A total of 1429 participants were White, 501 were Asian, and 128 were Black/African American.
You may also like...
Separating Fact from Fiction in the Management of Atopic Dermatitis
AD And Food Allergy Is A Distinct Endotype
Dupilumab significantly improved all assessed outcomes compared with placebo among White and Asian subgroups in all 3 trials, the researchers said. Among Black/African American participants, the researchers found dupilumab significantly improved EASI end points and mean Peak Pruritis NRS and DLQI scores compared with placebo, as well as showed positive numeric trends favoring dupilumab for all other end points.
In addition, dupilumab had an acceptable safety profile in all racial subgroups and was generally well tolerated. Serious adverse events occurred more frequently in the placebo group and discontinuation due to adverse events was rare.
“Significant clinical improvement and a favorable benefit-risk profile can be achieved with dupilumab treatment in patients of White, Asian, and Black/African American racial subgroups with moderate-to-severe AD inadequately controlled with topical medications,” the researchers said.
Alexis AF, Marta Rendon M, Silverberg JI, et al. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. J Drug Dermatol. 2019;18(8):804-813.